BFM
CDIO icon

Boothbay Fund Management’s Cardio Diagnostics CDIO Stock Holding History

Boothbay Fund Management’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-452
Closed -$14.4K – 2162
2022
Q4 		$14.4K Buy
+452
New +$48.8K ﹤0.01% 1927
2022
Q3 		– Sell
-8,000
Closed -$2.39M – 2268
2022
Q2 		$2.39M Hold
8,000
– – 0.06% 479
2022
Q1 		$2.38M Buy
+8,000
New +$2.36M 0.06% 507

Other funds holding CDIO

LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Boothbay Fund Management's CDIO Position: Q1 2023 in Review

Boothbay Fund Management sold out of Cardio Diagnostics (CDIO) in Q1 2023, closing a stake of 452 shares — an estimated $14.4K sold.

Boothbay Fund Management first reported a position in CDIO in Q1 2022 and held it in 3 quarters. The position peaked at $2.39M in Q2 2022. 11 funds tracked by Wall St. Rank hold CDIO as of Q1 2023.

  • Boothbay Fund Management reported no remaining Cardio Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 452 Cardio Diagnostics shares in Q1 2023, an estimated $14.4K.
  • Boothbay Fund Management first reported a position in Cardio Diagnostics in Q1 2022 and held it in 3 quarters.
  • Boothbay Fund Management's Cardio Diagnostics position peaked at $2.39M in Q2 2022.
  • 11 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.